Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

459 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
8-Piperazinyl-2,3-dihydropyrrolo[3,2-g]isoquinolines: potent, selective, orally bioavailable 5-HT1 receptor ligands.
Heightman TD, Gaster LM, Pardoe SL, Pilleux JP, Hadley MS, Middlemiss DN, Price GW, Roberts C, Scott CM, Watson JM, Gordon LJ, Holland VA, Powles J, Riley GJ, Stean TO, Trail BK, Upton N, Austin NE, Ayrton AD, Coleman T, Cutler L. Heightman TD, et al. Among authors: watson jm. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4370-4. doi: 10.1016/j.bmcl.2005.06.042. Bioorg Med Chem Lett. 2005. PMID: 16039851
Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.
Macdonald GJ, Branch CL, Hadley MS, Johnson CN, Nash DJ, Smith AB, Stemp G, Thewlis KM, Vong AK, Austin NE, Jeffrey P, Winborn KY, Boyfield I, Hagan JJ, Middlemiss DN, Reavill C, Riley GJ, Watson JM, Wood M, Parker SG, Ashby CR Jr. Macdonald GJ, et al. Among authors: watson jm. J Med Chem. 2003 Nov 6;46(23):4952-64. doi: 10.1021/jm030817d. J Med Chem. 2003. PMID: 14584946
3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity.
Atkinson PJ, Bromidge SM, Duxon MS, Gaster LM, Hadley MS, Hammond B, Johnson CN, Middlemiss DN, North SE, Price GW, Rami HK, Riley GJ, Scott CM, Shaw TE, Starr KR, Stemp G, Thewlis KM, Thomas DR, Thompson M, Vong AK, Watson JM. Atkinson PJ, et al. Among authors: watson jm. Bioorg Med Chem Lett. 2005 Feb 1;15(3):737-41. doi: 10.1016/j.bmcl.2004.11.030. Bioorg Med Chem Lett. 2005. PMID: 15664848
Studies on a series of potent, orally bioavailable, 5-HT(1) receptor ligands.
Ward SE, Johnson CN, Lovell PJ, Scott CM, Smith PW, Stemp G, Thewlis KM, Vong AK, Watson JM. Ward SE, et al. Among authors: watson jm. Bioorg Med Chem Lett. 2007 Sep 15;17(18):5214-7. doi: 10.1016/j.bmcl.2007.06.078. Epub 2007 Jun 30. Bioorg Med Chem Lett. 2007. PMID: 17629698
SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist.
Scott C, Langmead CJ, Clarke KL, Wyman P, Smith PW, Starr KR, Dawson LA, Price GW, Hagan JJ, Watson J. Scott C, et al. Neuropharmacology. 2006 Jun;50(8):984-90. doi: 10.1016/j.neuropharm.2006.01.008. Epub 2006 Mar 20. Neuropharmacology. 2006. PMID: 16546225
Serotonergic targets in depression.
Middlemiss DN, Price GW, Watson JM. Middlemiss DN, et al. Among authors: watson jm. Curr Opin Pharmacol. 2002 Feb;2(1):18-22. doi: 10.1016/s1471-4892(01)00116-3. Curr Opin Pharmacol. 2002. PMID: 11786304 Review.
459 results